Next Article in Journal
Genomic and Phenotypic Alterations of the Neuronal-Like Cells Derived from Human Embryonal Carcinoma Stem Cells (NT2) Caused by Exposure to Organophosphorus Compounds Paraoxon and Mipafox
Next Article in Special Issue
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
Previous Article in Journal
Effect of Nanoparticles Exposure on Fractional Exhaled Nitric Oxide (FENO) in Workers Exposed to Nanomaterials
Previous Article in Special Issue
Traumatic Brain Injury Pathophysiology and Treatments: Early, Intermediate, and Late Phases Post-Injury
Int. J. Mol. Sci. 2014, 15(1), 895-904; doi:10.3390/ijms15010895
Communication

Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury

1,2,* , 2,3
, 4
, 4
, 1,2
, 2
, 4
, 4
 and 1,2
Received: 29 October 2013; in revised form: 3 January 2014 / Accepted: 6 January 2014 / Published: 9 January 2014
(This article belongs to the Special Issue Pathology and Treatment of Central Nervous System Diseases)
View Full-Text   |   Download PDF [357 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Traumatic brain injury (TBI) occurs in response to an acute insult to the head and is recognized as a major risk factor for Alzheimer’s disease (AD). Indeed, recent studies have suggested a pathological overlap between TBI and AD, with both conditions exhibiting amyloid-beta (Aβ) deposits, tauopathy, and neuroinflammation. Additional studies involving animal models of AD indicate that some AD-related genotypic determinants may be critical factors enhancing temporal and phenotypic symptoms of TBI. Thus in the present study, we examined sub-acute effects of moderate TBI delivered by a gas-driven shock tube device in Aβ depositing Tg2576 mice. Three days later, significant increases in b-amyloid deposition, glycogen synthase-3 (GSK-3) activation, phospho-tau, and pro-inflammatory cytokines were observed. Importantly, peripheral treatment with the naturally occurring flavonoid, luteolin, significantly abolished these accelerated pathologies. This study lays the groundwork for a safe and natural compound that could prevent or treat TBI with minimal or no deleterious side effects in combat personnel and others at risk or who have experienced TBI.
Keywords: traumatic brain injury; Alzheimer’s disease; amyloidogenesis; tauopathy; GSK; neuroinflammation; luteolin traumatic brain injury; Alzheimer’s disease; amyloidogenesis; tauopathy; GSK; neuroinflammation; luteolin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Sawmiller, D.; Li, S.; Shahaduzzaman, M.; Smith, A.J.; Obregon, D.; Giunta, B.; Borlongan, C.V.; Sanberg, P.R.; Tan, J. Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury. Int. J. Mol. Sci. 2014, 15, 895-904.

AMA Style

Sawmiller D, Li S, Shahaduzzaman M, Smith AJ, Obregon D, Giunta B, Borlongan CV, Sanberg PR, Tan J. Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury. International Journal of Molecular Sciences. 2014; 15(1):895-904.

Chicago/Turabian Style

Sawmiller, Darrell; Li, Song; Shahaduzzaman, Md; Smith, Adam J.; Obregon, Demian; Giunta, Brian; Borlongan, Cesar V.; Sanberg, Paul R.; Tan, Jun. 2014. "Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury." Int. J. Mol. Sci. 15, no. 1: 895-904.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert